binodenoson and Hyperemia

The purpose of this study was to define binodenoson dosing regimens that produce coronary hyperemia comparable to those of adenosine and that are tolerated well by patients. An open-label, randomized, parallel-group, multicenter study enrolled adult patients who had completed diagnostic cardiac catheterization. Coronary blood flow velocity (CBFV) was measured with a Doppler flow wire, and CBFV reserve was determined before binodenoson administration. Patients (n = 133) received a 3-minute infusion of 0.3, 0.5, or 1 microg/kg/min or a bolus intravenous injection of 1.5 or 3 microg/kg. Coronary hyperemic responses were evident within seconds of administering binodenoson, and the magnitudes and durations of coronary hyperemic responses were dose related. The 1.5- and 3-microg/kg doses, by infusion or bolus, produced maximal coronary hyperemia equivalent to CBFV reserve. All doses transiently decrease blood pressure and increased heart rate and rate-pressure product. In conclusion, the 1.5-microg/kg binodenoson bolus dose produced nearly maximal coronary hyperemia by 4.5 +/- 3.7 minutes that was sustained for 7.4 +/- 6.86 minutes, was accompanied by modest changes in blood pressure, heart rate, and rate-pressure product, and produced no adverse changes on electrocardiogram, including no second- or third-degree atrioventricular block.

Topics: Adenosine; Adenosine A2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Flow Velocity; Blood Pressure; Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Resistance

Topics: Adenosine; Adenosine A2 Receptor Agonists; Blood Flow Velocity; Blood Pressure; Coronary Circulation; Heart Rate; Humans; Hyperemia; Myocardial Reperfusion; Vascular Resistance; Vasodilator Agents